Opinion|Videos|May 7, 2025
Advanced Treatment Options in Parkinson Disease
Panelists discuss how physicians typically consider advanced Parkinson disease treatments when conventional therapies fail to adequately control motor fluctuations, highlighting challenges such as adverse effects, device-related complications, and patient selection criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Advanced Treatment Considerations and Challenges
Timing for Advanced Treatment Consideration:
- When standard oral medications fail to adequately control motor fluctuations
- When optimal oral therapy causes intolerable adverse effects
- When quality of life is significantly impacted despite medication optimization
- Usually 5 to 10 years into disease course
- When off time exceeds 2 hours daily despite optimization
Challenges With Current Treatment Options:
- Narrow therapeutic window of levodopa (balancing efficacy vs dyskinesias)
- Pharmacokinetic limitations of oral medications
- Gastrointestinal dysfunction affecting medication absorption
- Cognitive decline limiting complex medication regimens
- Peripheral adverse effects (orthostasis, nausea, impulse control disorders)
- Patient adherence to complex regimens
- Surgical interventions: patient selection criteria, resource limitations, expertise availability
- Cost and insurance coverage barriers for advanced therapies
Advertisement
Related to this article
A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Closing the Gaps in Cluster Headache Care: Jennifer Fokas, MD; Minali Nigam, MD
2
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
3
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
4
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
5